Avidity Partners Management LP Phathom Pharmaceuticals, Inc. Transaction History

Avidity Partners Management LP

$194 Million
Q3 2025

A detailed history of Avidity Partners Management LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Avidity Partners Management LP holds 306,000 shares of PHAT stock, worth $4.5 Million. This represents 1.81% of its overall portfolio holdings.

Number of Shares

306,000

Previous 1,064,500 71.25%

Holding current value

$4.5 Million

Previous $10.2 Million 65.71%

% of portfolio

1.81%

Previous 2.76%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$7.83 - $12.89 $5.94 Million - $9.78 Million	-758,500 Reduced 71.25%	306,000 $3.5 Million
Q2 2025 Aug 14, 2025	BUY	$2.29 - $10.9 $605,705 - $2.88 Million	264,500 Added 33.06%	1,064,500 $10.2 Million
Q1 2025 May 15, 2025	SELL	$4.22 - $7.74 $2.49 Million - $4.57 Million	-590,100 Reduced 42.45%	800,000 $5.02 Million
Q4 2024 Feb 14, 2025	SELL	$7.45 - $18.94 $3.09 Million - $7.85 Million	-414,393 Reduced 22.96%	1,390,100 $11.3 Million
Q3 2024 Nov 14, 2024	BUY	$10.25 - $19.5 $1.89 Million - $3.6 Million	184,493 Added 11.39%	1,804,493 $32.6 Million
Q2 2024 Aug 14, 2024	SELL	$8.97 - $12.05 $1.03 Million - $1.39 Million	-115,000 Reduced 6.63%	1,620,000 $16.7 Million
Q1 2024 May 15, 2024	BUY	$6.21 - $11.05 $83,338 - $148,291	13,420 Added 0.78%	1,735,000 $18.4 Million
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $728,917 - $1.12 Million	104,280 Added 6.45%	1,721,580 $15.7 Million
Q3 2023 Nov 14, 2023	SELL	$10.26 - $15.7 $3.41 Million - $5.22 Million	-332,400 Reduced 17.05%	1,617,300 $16.8 Million
Q2 2023 Aug 14, 2023	SELL	$7.28 - $14.32 $719,992 - $1.42 Million	-98,900 Reduced 4.83%	1,949,700 $27.9 Million
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $919,834 - $1.84 Million	148,600 Added 7.82%	2,048,600 $14.6 Million
Q4 2022 Feb 14, 2023	SELL	$9.18 - $11.53 $62,424 - $78,404	-6,800 Reduced 0.36%	1,900,000 $21.3 Million
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $83,980 - $157,430	-13,000 Reduced 0.68%	1,906,800 $21.1 Million
Q2 2022 Aug 15, 2022	SELL	$6.2 - $15.5 $162,440 - $406,100	-26,200 Reduced 1.35%	1,919,800 $16.2 Million
Q1 2022 May 16, 2022	BUY	$11.55 - $20.06 $577,500 - $1 Million	50,000 Added 2.64%	1,946,000 $26.5 Million
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $33.8 Million - $62.9 Million	1,896,000 New	1,896,000 $37.3 Million
Q1 2021 May 17, 2021	SELL	$33.86 - $48.68 $5.16 Million - $7.42 Million	-152,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$33.22 - $50.26 $5.07 Million - $7.66 Million	152,500 New	152,500 $5.07 Million

Others Institutions Holding PHAT

# of Institutions

152

Shares Held

65.3M

Call Options Held

1.15M

Put Options Held

170K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $575M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.

Account

Avidity Partners Management LP Phathom Pharmaceuticals, Inc. Transaction History